Children's Oncology Group's 2023 blueprint for research: Rare tumors

Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30574. doi: 10.1002/pbc.30574. Epub 2023 Jul 17.

Abstract

The Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.

Keywords: Adrenocortical carcinoma; Children's Oncology Group; colorectal carcinoma; nasopharyngeal carcinoma; pleuropulmonary blastoma; rare cancer; rare tumor; retinoblastoma; thyroid cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adrenal Cortex Neoplasms*
  • Child
  • Humans
  • Medical Oncology
  • Nasopharyngeal Neoplasms*
  • Retinal Neoplasms*
  • Thyroid Neoplasms*